Proposed Section Structure
This article is organized into the following sections: Highlights; Background and clinical importance; Study design and methods; Key findings; Clinical interpretation; Strengths and limitations; Implications for practice and policy; Conclusion; Funding and trial registration; References.
Highlights
COPD was associated with shorter life expectancy in a large pooled US population study, and the reduction became progressively larger with increasing GOLD stage.
At age 65 years, estimated life expectancy declined from 21.5 years in people without airflow obstruction to 20.0 years in GOLD 1, 16.4 years in GOLD 2, 13.1 years in GOLD 3, and 10.7 years in GOLD 4.
Years of life lost ranged from 0.71 years in GOLD 1 to 7.12 years in GOLD 4, and losses for GOLD 2-4 were similar to or greater than those associated with hypertension, diabetes, obesity, and cigarette smoking.
The association was observed not only in ever-smokers but also in adults who never smoked, reinforcing that COPD is a major life-limiting condition beyond its traditional link to tobacco exposure.
Background and Clinical Importance
Chronic obstructive pulmonary disease remains one of the leading causes of death worldwide and in the United States. Although clinicians recognize COPD as a progressive disease associated with dyspnea, exacerbations, functional decline, and multimorbidity, discussions with patients often rely on relatively imprecise prognostic language. Mortality risk estimates are available from prior epidemiologic and clinical cohorts, but robust life-expectancy estimates that can be communicated to patients and applied to population planning have been more limited.
This gap matters clinically. Patients ask practical questions: How serious is my disease? What does my spirometry mean for my future? How does COPD compare with other chronic conditions? These questions influence smoking cessation decisions, vaccine uptake, pulmonary rehabilitation participation, advance care planning, and treatment adherence. From a policy perspective, life expectancy and years of life lost are also more intuitively interpretable than hazard ratios alone when estimating disease burden.
The present study by Bhatt and colleagues addresses this need by quantifying life expectancy and years of life lost across COPD severity stages in a large pooled cohort of US adults followed longitudinally for mortality. Importantly, the analysis also compares the burden of COPD with other familiar chronic risk factors and diseases, including hypertension, diabetes, obesity, and cigarette smoking.
Study Design and Methods
Design and population
This was a cohort study using the National Heart, Lung, and Blood Institute Pooled Cohorts Study, which harmonized data from 8 US general population cohorts. Participants were enrolled between 1983 and 2011, were aged 17 to 98 years at baseline, and were followed through 2020. The analytic sample included 45,886 participants, of whom 25,827 were women, representing 56.3% of the cohort. Mean age at baseline was 52.4 years.
Over a median follow-up of 15.2 years, with an interquartile range of 9.7 to 27.1 years, 13,869 participants died. COPD was present in 8,058 individuals, corresponding to 17.6% of the cohort.
Exposure definition
COPD was defined spirometrically as a prebronchodilator forced expiratory volume in 1 second to forced vital capacity ratio less than 0.70. Disease severity was staged according to Global Initiative for Chronic Obstructive Lung Disease recommendations. The use of prebronchodilator spirometry is epidemiologically practical and common in large cohorts, though it is not identical to the postbronchodilator approach typically recommended for clinical diagnosis.
Outcome and modeling approach
The primary outcome was survival from the time of initial spirometry. The investigators used a parametric proportional hazards model with a Gompertz baseline hazard function. This choice is notable because Gompertz models are well suited to adult mortality, where hazard generally rises exponentially with age. Rather than focusing only on relative risk, the model was used to derive adjusted survival curves and estimate life expectancy.
Multivariable analyses adjusted for demographics, educational attainment, body mass index, smoking status, pack-years of smoking, diabetes, hypertension, and hypercholesterolemia. Years of life lost were calculated relative to individuals without airflow obstruction. The study also examined whether the decrement in life expectancy differed between never-smokers and ever-smokers.
Key Findings
Life expectancy falls progressively with COPD severity
The central finding was a clear severity gradient in life expectancy. In age-adjusted models, a person aged 65 years without COPD was estimated to have a mean life expectancy of 21.5 years. This fell to 20.0 years for GOLD stage 1, 16.4 years for GOLD stage 2, 13.1 years for GOLD stage 3, and 10.7 years for GOLD stage 4.
The corresponding 95% confidence intervals were narrow for the lower stages and wider for GOLD 4, as expected from the smaller number of individuals with very severe disease: 21.3 to 21.6 years without COPD, 19.7 to 20.4 years for GOLD 1, 16.1 to 16.8 years for GOLD 2, 12.5 to 13.8 years for GOLD 3, and 8.9 to 12.6 years for GOLD 4.
These estimates translate a familiar spirometric classification into a clinically meaningful survival framework. Put plainly, a 65-year-old with moderate airflow obstruction had an expected survival several years shorter than a peer without obstruction, and the decrement became pronounced in severe and very severe disease.
Years of life lost increase from mild to very severe disease
Compared with participants without airflow obstruction, estimated years of life lost were 0.71 years for GOLD stage 1, 2.58 years for GOLD stage 2, 5.07 years for GOLD stage 3, and 7.12 years for GOLD stage 4. The 95% confidence intervals were 0.34 to 1.08, 2.21 to 2.95, 4.39 to 5.74, and 5.21 to 9.04, respectively.
This pattern is clinically intuitive but important to quantify. Mild COPD carried a measurable but relatively modest decrement in longevity, whereas moderate and severe disease were associated with substantial life-years lost. The transition from GOLD 1 to GOLD 2 appears especially meaningful, suggesting that the burden becomes much more tangible once airflow limitation reaches moderate severity.
COPD burden extends beyond smoking-associated disease
One of the most important observations was that comparable decreases in life expectancy were seen in people with COPD who had never smoked and in those who had ever smoked. This finding supports an increasingly recognized view of COPD as a heterogeneous syndrome with multiple pathways, including biomass exposure, occupational exposure, environmental pollution, impaired lung growth, prior respiratory infection, asthma-related airway remodeling, and social determinants of health.
For clinicians, this result is a reminder not to reserve suspicion of COPD or discussions of prognosis only for smokers. Patients who have never smoked but have chronic dyspnea, cough, recurrent respiratory symptoms, or impaired spirometry may still face substantial long-term risk.
How COPD compares with other common chronic conditions
The study usefully placed COPD in context by comparing years of life lost with those associated with other chronic diseases or risk factors. Years of life lost were estimated as 2.7 years for hypertension, 4.1 years for diabetes, 0.5 years for obesity, and 5.5 years for cigarette smoking.
Against these benchmarks, GOLD stages 2 through 4 were associated with years of life lost that were similar to or greater than those of hypertension, diabetes, obesity, and smoking. This is a striking comparison because COPD is often undertreated and underrecognized relative to these conditions, despite a burden that is clearly competitive with them in survival terms.
Clinical Interpretation
Why these findings matter in routine care
This study provides clinicians with a more concrete way to frame the seriousness of COPD. For many patients, “higher mortality risk” is abstract, whereas “several years of life lost” is easier to understand. Such framing can improve shared decision-making around smoking cessation, inhaled therapy adherence, vaccinations, pulmonary rehabilitation, physical activity, nutritional optimization, and early palliative care discussions when appropriate.
The data also reinforce the practical importance of early identification. If moderate COPD already carries a meaningful reduction in life expectancy, there is a strong argument for earlier spirometry in symptomatic patients and more aggressive implementation of evidence-based interventions once disease is recognized.
Relation to guideline-based care
Current GOLD guidance emphasizes that COPD assessment should integrate symptom burden, exacerbation history, spirometry, and comorbidity management. This study does not replace that multidimensional approach, but it strengthens the prognostic value of spirometric severity. It also supports the broader guideline message that COPD is a systemic, high-impact chronic illness requiring longitudinal management rather than episodic symptom treatment.
Beyond pharmacotherapy, prognosis in COPD is influenced by exacerbation frequency, exercise limitation, frailty, cardiovascular disease, nutritional status, and access to care. The present findings should therefore be interpreted as average survival estimates within adjusted models, not deterministic predictions for individual patients. A patient with GOLD 2 disease who quits smoking, completes pulmonary rehabilitation, maintains vaccination, avoids exacerbations, and has good comorbidity control may fare better than the average estimate suggests.
Public health significance
The comparison with diabetes, hypertension, obesity, and smoking has substantial public health implications. COPD often receives less preventive and chronic disease management attention than these more prominently screened conditions. Yet the observed loss of life expectancy suggests that health systems should treat spirometry-confirmed airflow obstruction as a high-priority chronic disease state. This includes improving access to smoking cessation services, reducing exposure to air pollutants, supporting occupational protections, and expanding pulmonary rehabilitation infrastructure.
Strengths and Limitations
Major strengths
The study has several important strengths. First, it drew from a very large pooled sample of general population cohorts rather than a narrowly selected clinical trial population, which improves relevance to real-world disease burden. Second, follow-up was long, extending through 2020, allowing robust mortality ascertainment. Third, the use of a parametric survival approach enabled life expectancy estimation rather than reporting only relative hazards. Fourth, the analysis adjusted for major demographic, socioeconomic, smoking-related, and cardiometabolic confounders.
Key limitations
Several limitations deserve attention. The diagnosis of COPD was based on a fixed prebronchodilator FEV1/FVC ratio below 0.70. This may overclassify obstruction in some older adults and underclassify younger adults compared with lower-limit-of-normal approaches, and it does not exclude asthma or reversible obstruction as cleanly as postbronchodilator testing. Therefore, some misclassification is possible.
Second, residual confounding is likely. Even with extensive covariate adjustment, factors such as occupational exposures, environmental pollution, respiratory symptoms, exacerbation history, treatment intensity, physical activity, income, and healthcare access may influence survival. Third, life expectancy estimates are population averages derived from model assumptions; they should not be applied mechanistically to individual patients without considering clinical context. Fourth, because the cohorts span several decades, changes in smoking prevalence, inhaled therapies, cardiovascular prevention, vaccination, and supportive care may affect contemporary generalizability.
Finally, the study focuses on all-cause survival and years of life lost, which are highly relevant outcomes, but it does not address cause-specific mortality, quality-adjusted life expectancy, or the competing contributions of exacerbations, emphysema burden, chronic bronchitis phenotype, and comorbidity clusters.
Implications for Practice and Policy
For frontline clinicians, the study supports several actions. First, perform spirometry in symptomatic adults and do not dismiss COPD risk in never-smokers. Second, communicate prognosis in a balanced but concrete way, using disease severity to motivate preventive and therapeutic engagement. Third, intensify management as airflow limitation worsens, especially from GOLD 2 onward, where years of life lost become more substantial. Fourth, optimize comorbidity care, because cardiovascular and metabolic disease likely compound mortality risk in COPD.
For health systems and policymakers, the results argue for elevating COPD within chronic disease programs. Underdiagnosis remains common, and access to pulmonary rehabilitation and smoking cessation treatment is uneven. If moderate to severe COPD carries a life-expectancy penalty that rivals or exceeds other major chronic diseases, then investment in case finding, environmental risk reduction, respiratory prevention, and multidisciplinary management is justified.
For researchers, future work should refine prognostic estimates using postbronchodilator spirometry, symptom burden, exacerbation history, imaging phenotypes, biomarkers, and treatment exposure. Prognosis in never-smokers with COPD is a particularly important area for deeper mechanistic study. Quality-of-life and disability-free life expectancy are also highly relevant next steps, since patients experience COPD not only through mortality but through cumulative symptom and functional burden.
Conclusion
This pooled US cohort study provides compelling evidence that COPD meaningfully shortens life expectancy, with progressively greater years of life lost at higher GOLD stages. The burden is not confined to smokers and, from moderate disease onward, is comparable to or greater than that associated with several other widely recognized chronic conditions. The practical message is straightforward: COPD is a major life-limiting disease, spirometric severity has real prognostic meaning, and earlier recognition and comprehensive management should be central goals in both clinical care and public health.
Funding and ClinicalTrials.gov
The study was conducted within the National Heart, Lung, and Blood Institute Pooled Cohorts Study. Specific funding details were not provided in the abstract supplied here. No ClinicalTrials.gov registration number was reported, which is consistent with the observational cohort design.
References
1. Bhatt SP, Sun Y, Wang Y, Balte PP, Schwartz JE, Cassano P, Chaves PH, Couper D, Jacobs DR, Kalhan R, Kaplan RC, Lloyd-Jones D, Newman AB, O’Connor GT, Sadatsafavi M, Umans JG, White WB, Yende S, Oelsner EC. Life Expectancy in Chronic Obstructive Pulmonary Disease. JAMA Internal Medicine. Published online May 17, 2026. PMID: 42143630. Available at: https://pubmed.ncbi.nlm.nih.gov/42143630/
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2025 Report. Available at: https://goldcopd.org
3. World Health Organization. Chronic obstructive pulmonary disease (COPD): key facts. Available at: https://www.who.int